Actinium's ATNM-400 achieves 93% tumor growth inhibition in preclinical ovarian cancer model

• Actinium Pharmaceuticals announced preclinical ATNM-400 results supporting development across lung, colorectal and ovarian cancers.
• In a KRAS-mutant lung cancer model, ATNM-400 with adagrasib achieved 105% tumor growth inhibition, versus 81% with ATNM-400 alone.
• Adding ATNM-400 to oxaliplatin and bevacizumab increased tumor growth inhibition to 72% from 25% in a poorly responsive colorectal cancer model.
• ATNM-400 monotherapy achieved 93% tumor growth inhibition in an ovarian cancer model, compared with 54% for bevacizumab.
• Following bevacizumab failure, ovarian cancer models showed 50% tumor growth inhibition with ATNM-400 monotherapy, supporting development in treatment-resistant disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY75977) on October 20, 2026, and is solely responsible for the information contained therein.